AMT 2003

Drug Profile

AMT 2003

Alternative Names: AMT - Auron; AMT-2003; Auron Misheil Therapy

Latest Information Update: 19 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Auron Healthcare
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Colorectal cancer; Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 02 Jun 2009 Interim efficacy and adverse events data from a phase II trial in Solid Tumours were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top